Stockreport

POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-a Targeted Clinical Program

POINT Biopharma Global Inc.  (PNT) 
PDF A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004’s Phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT65 [Read more]